A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

Mise à jour : Il y a 5 ans
Référence : NCT00416520

Femme et Homme

Extrait

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.


Critère d'inclusion

  • chronic kidney disease ,Hyperphosphatemia


Liens